MI HB4607

Requires health care providers ordering Lyme disease laboratory tests to perform both an enzyme-linked immunosorbent assay (ELISA) test and a western blot assay test.

Mandates providers give patients written materials before testing that include available treatment options, a list of physicians with Lyme disease expertise, and information on symptoms and complications.

Requires providers to provide patients a specific notice explaining that Lyme disease testing can produce false negative and false positive results, and that negative results do not necessarily mean absence of the disease.

Protects health care providers from administrative action for prescribing, administering, or dispensing oral long-term antibiotics or intravenous antibiotics for Lyme disease treatment.

Takes effect 90 days after enactment into law.